Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2019. szeptember 2., hétfő 09:22 |
Syntellix Asia and Chunli agree far-reaching co-operation to introduce and market innovative "quantum leap in implantology" MAGNEZIX® medtech devices in China (part 1) |
|
Singapore/Beijing, 2 September, 2019. (APA/OTS) - Milestone contract signed between leading Chinese orthopaedic medtech supplier and Singapore based Asian subsidiary and hub of German world-market and technology leader in the area of bioabsorbable metallic implants for use in orthopaedic and trauma surgery - Contract volume of more than 100 million euros - Significant patient benefit for millions of people targeted in China's vast medical technology market with world's biggest population of 1.5 billion people - According to international experts, MAGNEZIX® implants developed by Syntellix are "clinically superior", a "quantum leap in implantology" and the "new gold standard" - German Innovation Award has recently confirmed Syntellix' technology leadership and user orientation |
Today, a far-reaching co-operation contract was signed between
Syntellix Asia Pte. Ltd., the Singapore based Asian subsidiary and
hub of highly innovative German biomedical technology pioneer
Syntellix AG from Hannover and China's leading orthopaedic implant
supplier Beijing Chunlizhengda Medical Instruments Co., Ltd., with
the aim of tapping into the unlimited potential of the Chinese
med-tech market based on the globally unique magnesium-based implant
technology successfully developed by Syntellix, which has already
obtained product registration and market approval in 56 countries
worldwide.
The co-operation and distribution agreement foresees a very close
and intense co-operation in many areas including sales & marketing
and distribution in China as well as research & development,
academic projects and training activities in China, and also a
Sino-German exchange in order to promote the unique advantages of
Syntellix' magnesium alloy-based highly innovative implants. China,
with its population of 1.5 billion people, is expected to become the
biggest medical technology market in the world during the years to
come.
The minimum purchase quantity of the agreed milestone contract
amounts to more than 100 million euros over 5 years and thus
reflects the significant potential of Syntellix' technology as well
as Chunli's market access and distribution strength in the whole of
China. Both sides are confident to achieve even far higher sales
volumes than this contractually agreed minimum amount.
On the side of Chunli, the contract was signed by Mr Shi Chunbao,
the Founder, CEO, Director of the Boards and also Majority
Shareholder of Chunli. For Syntellix, Prof. Dr. Utz Claassen, the
Executive Chairman & CEO of Syntellix Asia Pte. Ltd., signed the
contract.
The signature of the co-operation and distribution agreement marks
a milestone in a year that for both companies has already seen major
breakthrough developments. As recently as on 28 May, Syntellix was
honoured with the German Innovation Award in Gold in the category
"Excellence in Business to Business - Medical Technologies" for its
MAGNEZIX® Pins magnesium implants at a gala event held at the Museum
of Technology in Berlin by the German Design Council, which was
founded in 1953 on the initiative of the German Federal Parliament.
All of Syntellix' globally unique MAGNEZIX® products are designed
to provide surgeons and patients with advanced implants that offer a
previously unattainable combination of metallic stability,
degradability and biocompatibility. In a widely acclaimed recent
academic publication, Syntellix bone screws were evaluated as being
"clinically superior" to the titanium implants commonly used. In
April of this year, at a conference in Surakarta/Java, Gowreeson
Thevendran, a leading surgeon from Singapore, based on his excellent
experience with these implants over several years, described the
magnesium technology developed by Syntellix as "the new gold
standard" in this area.
MAGNEZIX® bioabsorbable metal implants, based on a globally unique
patented magnesium alloy, dissolve completely in the bone. Unlike
conventional metal implants, the patient does not have to undergo a
second surgery to remove the implants. MAGNEZIX® implants degrade in
the human body and are converted into bone tissue. This means these
implants even support the healing process. Magnesium also has an
inhibitory effect on infection and is well tolerated; according to
the German Innovation Award jury, it is a "quantum leap in
implantology".
Chunli has recently added three new products to its already
comprehensive orthopaedic joint product range, all of which
successfully obtained product registration in China via the
fast-track process. Syntellix, similarly, already has been granted
the accelerated "innovative pathway" by the National Medical
Products Administration (NMPA), the regulatory authority responsible
for product registrations in China.
"Chunli is the best possible partner for us," said Prof. Dr. Utz
Claassen, Executive Chairman & CEO of Syntellix Asia Pte. Ltd.,
after signing the co-operation contract. "This co-operation is a
milestone for us that can impact upon and change the medical world.
We see it as a further confirmation that our magnesium technology
has the potential to completely replace conventional titanium, steel
or polymer implants in the long term. In doing so, Chunli and
Syntellix' strengths and interests are completely synergetic and
aligned. The combination of Chunli's significant resources and
unique market access in China with our globally unique magnesium
technology will be a great basis for us to uncompromisingly pursue
our winning approach and bring it to a successful conclusion for the
good of patients around the globe."(continues)
|
|
|
|
|
|
|
2019. szeptember 2., hétfő 09:22 |
Syntellix Asia and Chunli agree far-reaching co-operation to introduce and market innovative "quantum leap in implantology" MAGNEZIX® medtech devices in China (part 2) |
|
Singapore/Beijing, 2 September, 2019. (APA/OTS) - |
Chunli CEO Mr Shi Chunbao commented the pioneer transaction as
follows: "Chunli has seen a fantastic development in China and
beyond in recent years based on high quality, market proximity and
excellent products in key implant areas such as knee or hip joints.
With the Syntellix range of MAGNEZIX ® products that are completely
complementary for us and thus perfectly synergetic, we have the
basis to disrupt the implant market in China. German technology and
Chinese market understanding and market proximity are a unique
combination and a unique asset that, as I am convinced, will also
impress our shareholders and potential investors."
About Chunli:
Chunli is a leading Chinese orthopaedic and trauma med-tech device
manufacturer and marketeer. The company is listed in the Honk Kong
Stock Exchange and has undergone significant growth and a highly
successful value creation development in recent years. Chunli
employs more than 600 people of which more than 300 are working in
sales & marketing. The company engages approximately 600
sub-distributors and covers all provinces of China. It has access to
approximately 6,000 hospitals in the People's Republic. Chunli is
not only engaged in manufacturing and marketing & sales, but has
also developed a high reputation as a driver of research and
innovation: the company hosts, organizes and sponsors numerous
high-level academic events in China and beyond, and it is also
engaged in research and training activities at hospital, municipal,
provincial and national level. Chunli targets to be the leading
supplier of orthopaedic medical technology in China for the years to
come and has already made very significant progress towards this
goal. In 2018, the company achieved a market share of approximately
15 percent in China, and in 2019 it intends to become the market
leader in China in the market of orthopaedic and trauma implants.
About Syntellix:
Syntellix Asia Pte. Ltd. is the Asian subsidiary and hub of
Syntellix AG, Germany, an internationally operating medical
technology company with headquarters in Hannover, Germany, that is
undergoing dynamic growth. The company specialises in the research
and development and marketing and sales of highly innovative
transformable metallic implants. Products made from the company's
patented MAGNEZIX® are unique. In a widely acclaimed publication,
they were evaluated as being clinically superior to the titanium
implants commonly used. The implants degrade in the human body and
are transformed into the body's own bone tissue, and in doing so
offer an ideal combination of stability, elasticity and
bioabsorbability. In a conference in Surakarta/Java, a leading
surgeon from Singapore described the magnesium technology developed
and used by Syntellix as "the new gold standard" in this area.
Syntellix is the world's market and technology leader in the field
of bioabsorbable metallic orthopaedic implants and has already been
honoured with numerous important national and international awards
and prizes. These include the Innovation Award of the German Economy
2012/13, the Future Award 2016 of the German Healthcare Economy, the
German Medical Award 2017, the STEP Award 2017 and the Innovator of
the Year 2017 award - and now in 2019 the German Innovation Award in
Gold; the implants were also a winner in the Product of the Year
category of the Sustainability Award 2018 program.
Syntellix Asia Pte. Ltd. 2 Science Park Drive #02-10 Ascent Singapore 118222
T +65 6265 1970 F +65 6265 3346
info@syntellix.com www.syntellix.com
Board of Directors Prof. Dr. Utz Claassen Prof. Dr. Martin Kirschner Dr.-Ing. Jan-Marten Seitz Tan Bien Kiat Sun Meng Sheng
Executive Chairman & CEO Prof. Dr. Utz Claassen
For further information: press@syntellix.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|